Stock AVE AVECHO BIOTECHNOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Avecho Biotechnology Limited

Equities

AVE

AU0000047441

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 11:52:10 2024-04-28 pm EDT 		5-day change 1st Jan Change
0.004 AUD 0.00% Intraday chart for Avecho Biotechnology Limited 0.00% +14.29%
Mar. 25 Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial MT
Mar. 14 Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7.887 6.31 46.37 27.54 27.57 11.09
Enterprise Value (EV) 1 5.719 3.196 44.66 24.37 26.35 5.763
P/E ratio -1.97 x 8 x -17.1 x -7.89 x -11.5 x -2.31 x
Yield - - - - - -
Capitalization / Revenue 5.66 x 1.49 x 121 x 34.7 x 24.4 x 23.4 x
EV / Revenue 4.1 x 0.75 x 116 x 30.7 x 23.3 x 12.2 x
EV / EBITDA -1.31 x 2.86 x -15.6 x -8.18 x -12.5 x -1.78 x
EV / FCF -3.05 x 4.78 x -59.8 x -12.2 x -30.5 x -3.05 x
FCF Yield -32.8% 20.9% -1.67% -8.17% -3.28% -32.8%
Price to Book 2.02 x 1.33 x 17.5 x 6.07 x 11.4 x 1.74 x
Nbr of stocks (in thousands) 1,577,457 1,577,457 1,598,895 1,836,117 1,837,869 3,169,297
Reference price 2 0.005000 0.004000 0.0290 0.0150 0.0150 0.003500
Announcement Date 3/26/19 3/1/20 3/25/21 2/27/22 3/15/23 2/29/24
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.394 4.238 0.3846 0.7936 1.129 0.4736
EBITDA 1 -4.362 1.119 -2.87 -2.978 -2.106 -3.243
EBIT 1 -5.088 0.515 -3.407 -3.406 -2.336 -3.421
Operating Margin -364.91% 12.15% -885.8% -429.2% -206.86% -722.46%
Earnings before Tax (EBT) 1 -3.991 0.85 -2.635 -3.416 -2.342 -3.437
Net income 1 -3.991 0.85 -2.635 -3.416 -2.342 -3.437
Net margin -286.24% 20.06% -685.04% -430.46% -207.43% -725.7%
EPS 2 -0.002537 0.000500 -0.001700 -0.001900 -0.001299 -0.001515
Free Cash Flow 1 -1.878 0.6684 -0.7463 -1.992 -0.8644 -1.891
FCF margin -134.7% 15.77% -194.03% -250.96% -76.54% -399.3%
FCF Conversion (EBITDA) - 59.74% - - - -
FCF Conversion (Net income) - 78.64% - - - -
Dividend per Share - - - - - -
Announcement Date 3/26/19 3/1/20 3/25/21 2/27/22 3/15/23 2/29/24
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2.17 3.11 1.71 3.17 1.22 5.33
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.88 0.67 -0.75 -1.99 -0.86 -1.89
ROE (net income / shareholders' equity) -77.5% 19.6% -71.1% -95% -67.3% -78.1%
ROA (Net income/ Total Assets) -48.8% 6.36% -49.1% -49.5% -34% -40.1%
Assets 1 8.184 13.36 5.364 6.901 6.892 8.57
Book Value Per Share 2 0 0 0 0 0 0
Cash Flow per Share 2 0 0 0 0 0 0
Capex 1 0 - 0.01 0.2 0.05 -
Capex / Sales 0.03% - 1.34% 25.56% 4.7% -
Announcement Date 3/26/19 3/1/20 3/25/21 2/27/22 3/15/23 2/29/24
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AVECHO BIOTECHNOLOGY LIMITED Stock Avecho Biotechnology Limited
+14.29% 8.27M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AVE Stock
  4. Financials Avecho Biotechnology Limited